THRN Thorne Research: Forward Price-to-Revenue Multiple

Thorne HealthTech (THRN) forward P/S dynamics reflect current market expectations, where the value of 1.30 characterizes this level. High barriers to entry are established by biotest patents and strict FDA oversight. Process optimization is based on contract manufacturing and external IT services. Growing demand for longevity and premium supplements facilitates the scaling of sales under private status.

thorne.com - THRN Forward Price to Sales (period 07/04/2022 - 10/21/2023)

Metric breakdowns and analytics for Thorne Research (THRN)

- current price and projected stock value:

Stock Price Thorne HealthTech, Inc.|THRN - Average Forecast Price

- company stock capitalization data:

Market Valuation Thorne Research|THRN - Value Adjusted for Debt and Cash

- business book valuation details:

Book Value per Share Thorne HealthTech|THRN - Accounting Value of Company|Market Capitalization to Book Value Ratio thorne.com|THRN - Company Assets

- debt and solvency information:

- financial results and valuation multiples details:

THRN - Profit After Payment of Taxes|Projected Future Earnings Thorne HealthTech|THRN - Market Cap to Earnings|Forward P/E Multiple Thorne|THRN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Thorne Research|THRN - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Thorne HealthTech|THRN - Earnings per share for the last four quarters|Quarterly EPS earnings growth thorne.com|THRN - Earnings per share increase in current year|Net earnings per share growth forecast for next year Thorne HealthTech

- company sales and revenue statistics:

THRN - Company Sales Revenue|Company Projected Revenue Thorne HealthTech, Inc.|THRN - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple Thorne Research

Summary company analytics:Thorne HealthTech, Inc. (THRN)

To find fundamental support in Thorne HealthTech (THRN), it is essential to align the business's market value with expected revenues from personalized medicine and diagnostics. By analyzing the forward P/S valuation, an investor determines a fair capitalization range relative to future revenue, which allows for the distinction between genuine growth in wellness segment network effects and a dangerous overvaluation of the asset.

Competing companies

Forward P/S Multiple HIMS (Hims & Hers)|Hinge Health, Inc. (HNGE) - Market Cap to Future Revenue Ratio|TDOC: Forward Price-to-Revenue Multiple|Forward Price to Sales TALK (Talkspace Platform)|LFMD: Forward P/S Multiple|amwell.com - Forward Price to Sales|MGRX (Mangoceuticals Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio DarioHealth Corp DRIO|Forward P/S Multiple VSEE|Forward P/S Multiple Mobile-health Corp (MNDR)|Price-to-Projected Revenue Ratio Accolade, Inc. ACCD|biotricity.com - Price-to-Projected Revenue Ratio|LYT: Forward Price-to-Revenue Multiple|Ontrak Inc - Price to Expected Revenue Ratio|SHLT: Forward P/S Multiple